Loading quotes...
Forecast
The analysts' average price target is €5.11 (-74.17%). The median is €5.11 (-74.17%).
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
Yarrow Bioscience places share offering of about $150 million at $26 per share
Yarrow Bioscience has placed a public offering of 5,769,231 common shares at $26.00 per share, expected to raise approximately $150 million gross. The underwriting banks were granted a 30‑day option to purchase up to 865,384 additional shares; closing is expected on September 14, 2026. Net proceeds are intended primarily to fund research and development of the product pipeline, including the monoclonal antibody candidate YB‑101, and for general corporate purposes. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 84.99K | 45.18% |
| Gross profit | 79.74K | 36.20% |
| Net profit | -2.63M | 46.04% |
| EBITDA | -2.54M | 47.90% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €186.1M |
Number of shares | 9.3M |
52-week high/low | €41.70 - €14.21 |
Dividend yield | 1.69% |
Dividends TTM | €0.35 |
Beta | 2.07 |
P/E ratio | -0.96 |
PEG ratio | -0.01 |
P/B ratio | 0.88 |
P/S ratio | 434.72 |
Company profile
| Name | Yarrow Bioscience |
| CEO | Rebecca Velez Frey |
| Employees | 10 |
